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Background: In vivo animal models of familial amyotrophic lateral sclerosis (fALS) are widely used to delineate the
potential role that genetic mutations play in the neurodegenerative process. While these models are extensively
used for establishing the safety and efficacy of putative therapeutics during pre-clinical development, effective
clinical translation of pharmacological interventions has been largely unsuccessful.
Results: In this report we compare a recent cohort of G37R (line 29) mice generated from mating wild-type females
with transgenic males obtained commercially to a previous set of offspring produced with transgenic male breeders
from a colony established at a local collaborator’s facility. Commercially derived progeny presented with a tightly
clustered genomic signature for the mutant human superoxide dismutase1 transgene (hSOD1) locus, and exhibited
a greater than two-fold reduction in the number of transgene copies present in the genome compared to offspring
derived locally. Decrease in transgene levels corresponded with delayed ALS progression and a significant increase
in overall lifespan (146%).
Conclusions: These results highlight some key challenges inherent to the use of G37R (line 29) animals in
pre-clinical studies for the development of ALS therapeutics. Without stringent assessment of mutant SOD1 copy
number/protein levels, heterogeneity of transgene levels within cohorts may influence the behavioural and
pathological presentation of disease and thus calls to question the validity of any detected therapeutic effects.
Nuanced changes in mutant SOD1 copy number that currently remain unreported may undermine research
endeavours, delay efforts for clinical translation, and compromise the rigor of animal studies by limiting
reproducibility amongst research groups.
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Amyotrophic Lateral Sclerosis (ALS) is a progressive
paralytic disorder of unknown etiology marked by the
degeneration of motor neurons in the brain and spinal
cord. Approximately 5% of reported familial ALS cases
(fALS) are linked to genetic mutations and are inherited
in an autosomal dominant fashion [1]. Less than 20% of* Correspondence: pierre.zwiegers@gmail.com
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unless otherwise stated.these are linked to over 170 toxic gain-of-function muta-
tions in any of the five exons of the gene encoding the
Cu/Zn superoxide dismutase 1 (SOD1) enzyme [2], albeit
it a loss-of-function may also contribute to ALS pathobiol-
ogy [3]. Although the vast majority (90%) of ALS is spor-
adic (sALS) and has no known cause, these cases have
been reported to be clinically and neuropathologically in-
distinguishable from the inherited forms of the disease [4].
Animal models delineating disease-course specific pa-
rameters provide a glimpse into the mechanism(s) of
disease pathogenesis and can serve as a platform to ex-
plore etiological agents that augment disease presentation.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions found in fALS patients mimic the progressive nature
of the disease, aspects of motor neuron death, and histo-
pathological hallmarks associated with clinical ALS [5,6].
These animal models have been crucial in demonstrating
that it is not a reduction of dismutase activity per se that
predisposes the system to an ALS phenotype, but rather
the acquisition of novel toxic properties in the SOD1 pro-
tein product [7]. A recent study using the G37R mouse
model demonstrated that the fALS phenotype and related
histopathology is enhanced with an environmental agent
that is sufficient at producing a neurodegenerative pheno-
type alone [8]. The ability of in vivo models to provide a
glimpse into the mechanistic underpinnings of disease
pathogenesis underscores their value in the study of neu-
rodegenerative disorders and ultimately in translational
research for therapeutic development.
Several transgenic mouse models of fALS have been
generated which include animals harbouring the G93A
[9], G37R [10], G85R [11], and D90A mutations [12].
While all of these mouse models are characterized by
motor neuron loss and similar histopathological findings,
the G93A and G37R mutations are currently the most
widely used and have produced the most detailed pheno-
typic data (Tables 1 and 2).
Originally developed by Wong et al. [10], the trans-
genic G37R line retaining full SOD1 specific activity was
generated via PCR-directed mutagenesis. After micro-
injection into a fertilized murine embryo, multiple cop-
ies were randomly inserted into the genome; giving rise
to several founder lines exhibiting varying degrees of
mutant hSOD1 expression levels and the associated
neuropathology (Table 2). Early studies of these lines
showed a correlation between reduced expression levels
of the mutant hSOD1 locus and an attenuated presenta-
tion of ALS-associated pathologies within a defined
time frame [10].
Extended observations of additional founder lines which
express markedly reduced levels of the mutant transgeneTable 1 Progressive phenotypic correlates in the G93A murin
Genetic modification # of gene
copies
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*V. Little evidence of vacuolar pathology at this late stage; **V. Little vacuolar pathofail to recapitulate any features of motor neuron degener-
ation and do not present with pathological outcomes [10].
This initial work correlating disease presentation with the
degree of mutant hSOD1 expression has demonstrated
that the aberrant phenotype is highly dependent upon the
number of defective SOD1 copies randomly inserted into
the genome when the transgenic line is established. In
addition, mutant hSOD1 expression levels are affected by
rare and spontaneous intralocus recombination events at
the meiotic level which have been shown to reduce trans-
gene copy number and result in the attenuated presenta-
tion of ALS-associated pathologies [7,17].
Although transgenic mice have been instrumental in
delineating the underlying causal mechanism(s) of ALS
pathogenesis, scientific data from research using mutant
SOD1 mouse models may have limited translational ap-
plicability. A multitude of promising therapeutic strategies
with demonstrated efficacy in the mouse have failed when
assessed in human clinical trials [18,19]. Although trans-
genic mouse models recapitulate many prominent features
of ALS, unlike clinical cases, each of these requires a sig-
nificant overexpression of the mutant locus to elicit the
neurodegenerative disease process, and is subsequently
sensitive to transgene dosage effects [17]. Furthermore,
given that such a small fraction of all ALS cases arise
due to genomic anomalies in the hSOD1 locus, the best
characterized mutant SOD1 models may have limited
reliability for translational research on potential ALS
therapies and questionable applicability to sporadic ALS
research [19].
To date, discrepancies between various pre-clinical effi-
cacy studies using transgenic hSOD1 mice have hampered
clinical translation of potential therapeutic compounds.
[18-20]. A survey of 25 studies involving line 29 G37R
animals over the past two decades indicates that crucial
information such as transgene copy number or level of en-
zyme activity are not usually quantifiably determined or
reported (Figure 1). Candid disclosure of these parameters
is crucial in assuring the scientific rigor and replicability ofe model of ALS1
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Table 2 Progressive phenotypic correlates in the G37R murine model of ALS1
Age at pathology (d)










Genomic hSOD1 G37R(42) [10] 12.3 14.5 106-121 77 105 77
Genomic hSOD1 G37R(9) [10] 6.2 9 152-183 70 105 35
Genomic hSOD1 G37R(106) [10] 5.3 7.2 167-228 189 126 77
Genomic hSOD1 G37R(29) [10] 5 7 183-243 none 133 77
Genomic hSOD1 wild-type (76) [10] 10.5 9.2 None by 548d none none none
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modalities. In the absence of stringent experimental
design and reporting parameters, the utility of these
models in delineating potential therapeutic avenues may
be limited [21,22].
To underscore these challenges, we report on the ALS
phenotype of progeny derived from commercially ob-
tained G37R (line 29) breeders with unexpected deficits
in genomic mutant hSOD1 levels and discuss the poten-
tial implications of this data for the discovery of effective
ALS therapies. We intend that the results described in
this report will stir discussion on the appropriate consid-
erations for ALS research using transgenic hSOD1 mice
in an evolving clinical therapeutics context.
Results
Varied hSOD1 transgene levels in collaborator- and
commercially derived G37R (line29) progeny
Progeny generated from breeders obtained from a local
collaborator demonstrated a mean signal (2ΔCt) of 33.5
(males) and 34.0 (females), while the signal from offspringFigure 1 Literature survey for details regarding the genomic SOD1 G
Genome Informatics database over the preceding two decades in referenc
been characterized, (2) SOD1 protein and/or aggregate levels are only asse
values regarding relative transgene presence are reported.generated from commercial breeders was 16.3 (males) and
13.2 (females); with a distribution that was relatively
tightly clustered (Figure 2). Thus, the cohort of line 29
progeny that our group had generated from commercially
obtained G37R male breeders exhibited more than a two-
fold decrease in the relative hSOD1 copy number for both
sexes when compared with progeny derived from a col-
laborator’s breeding colony (Figure 2). Differences in
the relative abundance of the transgene locus between
sexes within either progeny group were not statistically
significant (Figure 2). Conversely, both intra- and inter-
sex comparisons between progeny groups revealed a sig-
nificant relative difference in transgene copy number,
with commercially derived progeny exhibiting a signifi-
cantly diminished genomic hSOD1 signature (Figure 2;
p < 0.01 or p < 0.001).
Delayed symptom onset and increased lifespan
correspond to reduced transgene levels
Due to the temporal progression of disease phenotype in
affected mice, neuronal degeneration ultimately results37R locus. A review of publications (n = 25) listed on the Mouse
e to G37R line 29 animals reveals: (1) discrete copy numbers have not
ssed in half of the studies, and (3) given a genotype assessment, no
Figure 2 Comparisons of qualitative genotyping for the mutant
hSOD1 locus in two independently-derived colonies. Progeny
derived from commercial breeders exhibited more than a two-fold
decrease in the genomic G37R signature compared to collaborator
derived offspring. Results are presented as the relative difference
between the PCR cycle threshold (CT) values of the housekeeping
(CJUN) and target (mutant SOD1) genes, raised to the second
power. Kruskal-Wallis non-parametric analysis followed by Dunn’s
Multiple Comparison test, indicated significant inter-source differences
(p < 0.001, 0.01) while failing to differentiate loci heterogeneity from
within each source. Collaborator- ♂ vs. Commercial-♂ (p < 0.001);
Collaborator- ♂ vs. Commercial-♀ (p < 0.001); Collaborator- ♀ vs.
Commercial-♂ (p < 0.01); Collaborator- ♀ vs. Commercial-♀ (p < 0.001).
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humane experimental endpoint at which the animal can
no longer self-correct after being placed on its side. Com-
paring the survival curves between collaborator- and
commercially derived progeny indicates that the relative
amount of hSOD1 transgene copies within the genome
can have a significant effect on the presentation of an
ALS phenotype. Kaplan-Meier survival analysis indi-
cated a 146% increase of mean lifespan in commercially
derived progeny compared to offspring generated from
a collaborator’s colony (Figure 3A). Linear regression
analysis demonstrates a slightly negative correlation be-
tween the abundance of hSOD1 transgene and overall
subject longevity (r2 = 0.4991, significant non-zero slope:
p < 0.0001) (Figure 3B).
We defined disease onset as the time point at which
each animal had reached its peak body mass prior to pro-
gressive disease-related atrophy and loss of body mass. Al-
though commercially derived male progeny exhibited a
significant increase in lifespan compared to female mice,
there was no difference in disease onset between sexes
(Figure 4). Additionally, males and females derived from
commercial breeders exhibited a similar delay betweenALS onset and termination (Figure 4; 267 days for males,
259 days for females).
Discussion
We identified several deviations from the expected onset
and progression of disease in mutant SOD1 G37R (line
29) progeny derived from the mating of commercial trans-
genic male breeders with congenic C57BL/6 females, and
explored sex differences within these deviations.
All transgenic G37R progeny generated from commer-
cial male breeders exhibited more than a two-fold reduc-
tion in transgene dosage, a significant delay in ALS onset,
and an attenuated rate of disease progression compared to
offspring derived from a colony of male breeders obtained
locally (Figures 3 and 4). Male and female progeny from
the commercially derived group exhibited ALS-like out-
comes at a similar time point. However, females experi-
enced a steeper rate of decline, and ultimately reached the
humane end point for euthanasia at an earlier time. This
observation is in contrast to other published works which
indicate that female animals generally survive longer than
their male counterparts [17,23].
We observed marked differences in the onset and pro-
gression of the diseased phenotype in our commercially
generated progeny compared to those observed in other
studies of G37R (line 29) animals. Under similarly de-
fined parameters, Ezzi et al. [24] reported disease onset
at 307 +/−6 days and a median lifespan of 376 days (2010)
which is a markedly earlier age of onset and endpoint
compared to our commercially derived cohort (onset at
335 +/−72 days; lifespan of 603 days; male and female
groups combined).
Transgenic hSOD1 animals exhibit an ALS phenotype
whose severity and timing depends on the number of
tandem transgene copies that incorporate into the gen-
ome following microinjection into a fertilized egg [7,17].
Two explanations can account for the attenuated ALS
phenotype observed in our commercially derived progeny.
First, widespread transgene loss within the genome may
have been mediated by rare intralocus cross-over events
during meiotic recombination when the colony was estab-
lished in our facility. In the G93A model, this is a relatively
rare occurrence, and changes in the number of transgene
copies can occur in approximately 3% of progeny gener-
ated [17]. Thus, 97 percent of all meiotic events resulting
in transgenic G93A -and presumably G37R- progeny do
not exhibit genomic loss of hSOD1 copies, and subse-
quently present with ALS symptoms within a well-defined
time span. Additionally, employing multiple breeding pairs
theoretically diminishes the possibility of this event oc-
curring and should assure transgene level homogeneity
throughout the colony.
Second, an alternate and perhaps more plausible ex-
planation is that the original commercial male breeders
Figure 3 Transgene dosage effects on life span. (A) Kaplan-Meier
survival analysis. Transgenic animals with a lower CT signal value ex-
hibited an increased survival time. Bonferroni correction for multiple
comparisons indicated a significant difference between animal
source and lifespan. Inter-sex comparisons show that collaborator
derived progeny with a higher CT signal value reached the endpoint
(inability to self-correct) after one year of age, while commercially
derived progeny with a lower CT signal value reached the endpoint
much later, beyond 1.5 years of age. ***p < 0.001. Collaborator- ♂ n = 8;
Collaborator- ♀ n = 5; Commercial-♂ n = 18; Commercial-♀ n = 17.
(B) Linear regression analysis reveals a negative correlation between
relative mutant SOD1 copy number and lifespan (p < 0.0001).
Collaborator n = 16; Commercial n = 28.
Figure 4 Disease progression in commercially derived transgenic
progeny. Kaplan-Meier analysis did not indicate a significant difference
between sexes for disease onset (p = 0.0926), although presentation
of disease symptoms was slightly later in males. Males exhibited an
increased lifespan compared to females (p < 0.0001). Commercial Male
n = 12; mean age of onset/lifespan: 357/624d; Commercial Female
n = 9 mean age of onset/lifespan: 304/563d).
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a colony with a reduced hSOD1 copy number. This re-
duced genomic load of the hSOD1 transgene would then
have been propagated though several rounds of breeding
in our study (Jackson Laboratory, personal communica-
tion). However, this is enigmatic as all the original JAX®
breeders used in our study exhibited tightly clustered
CT values that were similar to historical control samples
from G37R (line 29) mice, indicating comparabletransgene levels within the genome (Additional file 1:
Figure S1). To our knowledge, no data have been pub-
lished demonstrating the significantly attenuated ALS
disease progression in an entire cohort of G37R (line 29)
progeny bred from multiple breeding sets. This may be
because this is a truly novel presentation that has never
previously been observed through multiple rounds of
breeding in other facilities. Alternatively, a lack of reported
phenotypic deviations in the scientific literature may re-
semble a publication bias against data that do not conform
to established parameters.
Genomic variation in the G93A model
The G93A transgenic model of fALS is the most widely
chosen system for evaluating the pre-clinical efficacy of
potential ALS therapeutic agents owing to its rapid and
robust phenotype [18].
Characterization of the various G93A murine models
have clearly established that the number of transgene
copies randomly inserted into the genome can exert a
pronounced effect on the onset and rate of disease pro-
gression. Line G1, with 18 G93A hSOD1 genomic cop-
ies, exhibited the greatest increase in SOD1 enzymatic
activity, showed evidence of motor deterioration by ap-
proximately 3 months of age, and reached an end state
of hind limb paralysis at 150 days of age [9]. On the
other hand, line G20, with approximately 2 hSOD1 gen-
omic copies exhibited a 6-fold decrease in total SOD1
protein levels compared to the G1 line and expressed a
markedly delayed onset in disease phenotype [9].
Due to rare recombination events, the original G1 line
has since been mated to produce two sub-lines that have
Zwiegers et al. Journal of Negative Results in BioMedicine 2014, 13:14 Page 6 of 9
http://www.jnrbm.com/content/13/1/14either increased or decreased the number of hSOD1 copies
randomly inserted into the genome [5]. A mouse line with
a 40% increase in copy number (25 copies of the G93A
locus) produced a more severe ALS pathology (Table 1;
[15]), while a 30% reduction in copy number (13 copies of
the G93A locus) resulted in an attenuated ALS phenotype
as compared to the original G1 line (Table 1; [7]). These
findings have further established the effect of transgene
dosage and highlight the need for a deeper discourse on
genetic information in studies that use transgenic ani-
mals to model ALS.
Variations in hSOD1 transgene within the G93A
model have paved the way for creating alternate con-
trolled systems to study the progression of ALS path-
ology. However, without crucial information regarding
the abundance of hSOD1 sequences within the genome
of transgenic ALS models and/or the expression levels
of the locus, comparison of therapeutic efficacy studies
between various research groups will continue to face
discrepancies [21].
Modeling ALS to test putative therapeutics
Critical assessment of this experimental paradigm in the
study of ALS is the paramount focus of this discussion.
Mutations in the SOD1 locus account for only a fraction
of the population that are afflicted with ALS [1]. Nonethe-
less, researchers have largely focused on understanding
SOD1-mediated mechanisms of disease and postulated
that fALS and sALS arise from a common disease pathway
[4]. Similarly, transgenic mutant hSOD1 animal models
have gained widespread scientific interest for identifying
and testing putative therapeutic agents for clinical ALS.
Failure to demonstrate an efficacious treatment for ALS to
date has cast doubt on the utility of preclinical data for
therapeutic research [18]. In the discussion to follow,
we present three possible explanations for this failure in
therapeutic discovery.
Marked overexpression of mutant loci produces a severe
phenotype that is unresponsive to treatment and may not
be a reliable model for clinical ALS
As discussed previously, the onset and rate of disease
progression in murine models are dependent upon trans-
gene dosage. Thus, to produce a rapid and robust ALS
phenotype, the number of transgene copies introduced
into the genome need to be in excess of the endogenous
locus, leading to a marked overexpression of mutant
SOD1 products. Within the context of a significant over-
production of mutant SOD1 protein products, it may be
unreasonable to suppose that any therapeutic agent can
significantly impede the onset or progression of this
experimentally induced form of ALS. Alternatively, it is
possible that some pharmacological interventions which
failed to progress past the pre-clinical stage may havebeen worth pursuing in further efficacy studies since
fALS patients do not express the mutant SOD1 locus to
the degree observed in transgenic mice with multiple
hSOD1 genomic copies. Without significant pre-clinical
evidence for treatment efficacy in these models, it is un-
likely that therapeutic research will progress towards
clinical applications.
Furthermore, potential therapeutics discovered in pre-
clinical research may not adequately address the pathobio-
logical mechanisms inherent to clinical ALS. For example,
one of the main characteristics reported in animals with
higher mutant hSOD1 levels is the marked vacuolar de-
generation present in the spinal cord [5,10]. This type of
neuronal pathology is not corroborated in post mortem
fALS or sALS patient samples, and is typically explained
as a toxic artefact of mutant SOD1 overexpression since
transgenic animals with a lower copy number do not show
vacuolar degeneration [5,7,14,25]. It is possible that
vacuolar pathology in mutant hSOD1mice arises from
overexpression of the transgene to produce a more se-
vere disease pathology that is uncharacteristic of human
ALS cases. When taken together, a more severe pheno-
type expected from greater quantities of mutant loci
may not be a reliable model system to measure success
or failure in translational therapeutic studies.Genomic “noise” within animal cohorts may influence the
course of disease progression and biases outcomes from
therapeutics studies
Once the line is established, changes in genomic quantities
of the mutant SOD1 transgene are relatively infrequent
due to the improbability of intralocus meiotic recombin-
ation events. Experimental subjects with varying numbers
of transgene copies will diverge along a spectrum of trans-
gene expression. Outliers at either end of this spectrum
will affect overall measures of severity of the observed
ALS phenotype and may bias reports on the outcomes of
pre-clinical therapeutic trials. For example, the presence
of outliers with greater than average number of transgene
copies tends to increase the estimate of ALS severity, thus
decreasing the calculated efficacy of pre-clinical thera-
peutic tests and lowering the chance of discovering a
potential treatment. Conversely, outliers occupying the
opposite end of this spectrum would ultimately slant
therapeutic tests towards reporting significant results, a
false positive bias that has ethical, economic, and social
consequences. If there is no diligent assessment of trans-
gene dosage and/or mutant protein expression levels, it is
likely that any therapeutic results observed may be pri-
marily a function of mutant locus heterogeneity and the
corresponding disease phenotype (Additional file 2: Figure
S2). Hence nuanced changes in transgene levels that dic-
tate the onset and progression of neurodegeneration may
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various research groups.
fALS vs sALS
Mutations within the SOD1 locus account for nearly 1
in 5 of all fALS cases which translates roughly to 1% of
all clinical presentations of ALS [1,26]. Researchers have
proposed that fALS and sALS are clinically indistin-
guishable, and hence understanding the familial form
will illuminate possible neuropathological mechanisms
in sALS [27,28]. However, this view of an indistinguishable
clinical overlap amongst cases of diverse etiologies is prob-
lematic as disease pathways leading to degenerative cas-
cades may be different. For example, degenerating motor
neurons in sALS lack evidence of epitope-specific labelling
for misfolded SOD1 aggregates, and this suggest a patho-
logical dissimilarity from familial forms of the disease [29].
Additionally, the discovery of pathological ubiquitinated
TDP-43 inclusions, which are unique to sALS, further
supports the view for divergent disease mechanism(s) for
sALS and SOD1-related fALS [30]. Thus, pre-clinical
studies of therapeutic efficacy in models of genetic caus-
ality may have implications for other genetic models of
ALS, but are likely unable to provide meaningful results
that are translatable to sALS.
Conclusion
These results highlight key challenges for scientific rigor
in using mutant hSOD1 G37R (line 29) genetic animal
models to study putative ALS therapeutics and urge for
the critical evaluation of using genetic animal models to
test the efficacy of potential ALS therapies. More strin-
gent criteria are needed to ensure homogeneity of trans-
gene load and consistent SOD1 expression levels across
research studies to allow reliable comparisons. This
would identify sources of noise that, if included in data
analysis, would introduce biased findings based on errors
of standardization. Additionally, candid dissemination of
unexpected findings to the broader research community
is crucial to expediently redirect resources away from
non-productive research endeavours where outcomes
measuring therapeutic value are questionably biased by
variability in transgene copy number. Of key interest is
the tension between reports that fALS and sALS are
clinically and pathologically similar, and evidence that
they may arise from different disease pathways. Research
priorities should now be established to develop appro-
priate models of sporadic disease to improve scientific
understanding and refine therapeutic research efforts.
Materials and methods
Animal husbandry
All research methods involving animal research subjects
were in accordance with the established guidelines of theCanadian Council on Animal Care, and by the Animal
Care Committee of the University of British Columbia. All
procedures involving mice were done at the Jack Bell
Research Centre (Vancouver, British Columbia), in a
controlled environment: 12-hour light/dark cycle and a
temperature maintained at 21-22°C. Food (Purina Lab-
Diet®) and water were provided ad libitum. Palliative
care was initiated at the onset of minor gait perturba-
tions, and mice were given a high caloric gelatinous sub-
strate for nutrition and hydration.
All progeny were weaned at three weeks of age, and ear
punch samples were collected to identify transgenic off-
spring via an automated genotyping platform (Transnetyx,
TN). Samples were quantitatively genotyped against the
c-Jun housekeeping gene for mutant SOD1 presence (for-
ward primer: CAGTAACTGAGAGTTTACCCTTTGGT;
reverse primer: CACACTAATGCTCTGGGAAGAAAGA;
Cordova, TN). Results are reported as the relative differ-
ence between the cycle threshold values (CT) found in as-
says for the housekeeping and target gene of interest,
raised to the second power to account for the doubling
of target DNA during each cycle of the PCR process (i.e.
Signal = 2 (CTcJUN – CTmSOD)). ΔCT is an indication of
transgene presence relative to the house keeping gene of
choice.
Collaborator derived G37R (29) progeny
During 2009, a colony of mice heterozygous for the
G37R (line 29) locus were obtained from the laboratory
of Dr. Neil Cashman where the transgene was main-
tained with a regular breeding cycle. Male animals posi-
tive for the transgene were maintained on a C57BL/6
background and crossed with naïve C57BL/6 dams to
generate the requisite progeny. Employing multiple breed-
ing pairs was done to limit the relatively rare event of mei-
otic recombination which could lead to a loss of tandem
transgene hSOD1 copies. Once generated, the progeny
were housed independently.
Commercially derived G37R (29) progeny
In 2011, a total of six male B6.Cg-Tg(SOD1*G37R)29Dpr/J
(Jackson Laboratory) breeders were crossed with 20 wild-
type congenic C57BL/6 females (Jackson Laboratory) to
generate progeny that seeded the colony. Females were
utilized for 3 rounds of breeding to achieve adequate num-
bers of transgenic progeny. Due to facility space limita-
tions, offspring were housed in groups segregated by
sex. Various behavioural measures were assessed bi-
weekly. For the purpose of this report, disease onset in
this cohort was defined as the age at which subjects
reached their peak body mass preceding the progressive
weight loss that typifies ALS presentation in this model.
This measure provided the earliest and most consistent
measure of differentiation between transgenic and wild-
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the latency to fall from an elevated grid and assessing hind
limb splay when the animal is suspended by the tail.
Both sets of progeny were originally a part of two sep-
arate studies assessing the therapeutic applicability of up
regulating a neuronal growth factor in attenuating ALS
pathogenesis (to be reported in a future correspondence).
Briefly, at approximately 11 months of age, the collaborator
derived progeny received bilateral delivery of a lentiviral
vector carrying either a GFP (control group) or Progranu-
lin (experimental group) construct into both gastrocne-
mius muscles. As a follow-up study, commercially derived
progeny were exposed to a similar treatment paradigm at
approximately 3.5 months of age. In either case, animals
were monitored for behavioral outcomes and maintained
until the humane endpoint was reached.
Comparisons between treatment (Progranulin) and
control (GFP) groups did not establish a significant differ-
ence in terms of disease progression (Additional file 3:
Figure S3). Consequently, for the purposes of this report,
experimental and control animals from each progeny
set were grouped to evaluate the influence of transgene
dosage on lifespan and ALS presentation within the
G37R(29) model.Statistical analysis
Data were analyzed utilizing the GraphPad Prism soft-
ware platform (San Diego, CA). Differences in cycle
threshold values between sourced animals were assessed
with Kruskal-Wallis non-parametric analysis followed by
Dunn’s Multiple Comparison test since not all assump-
tions for the parametric one-way ANOVA were upheld.
Differences in survival and onset of phenotype were
assessed by the log rank test, with the requisite Bonferroni
correction for multiple comparisons. All animals eu-
thanized due to non-ALS pathologies such as severe
dermatitis or abnormal growths etc., were excluded from
survival analyses.Additional files
Additional file 1: Figure S1. Cycle threshold values of original
commercial male breeders utilized in seeding our transgenic G37R (line
29) colony as assayed by Jackson laboratory. Results are plotted against
CT values of historical control samples from G37R (line 29 and 42), G93A,
and G85R animals. G37R (line 29) animals exhibit some of the lowest
copy numbers of the hSOD1 transgene. Breeder males that seeded our
colony were found to be well within a 0.5 deviation in CT values, and as
such, are deemed to retain comparable levels of the transgene as
historical G37R (line 29) controls (outlined region).
Additional file 2: Figure S2. Proposed model explaining pre-clinical
outcomes assessed in transgenic animals. It is possible the therapeutic
effect (or lack thereof) seen in these animal models may primarily be a
function of variations in mutant locus copy number and the corresponding
diseased phenotype. Outliers at either end of the transgene expression
spectrum will undermine replication studies and effective clinical translation.Additional file 3: Figure S3. Lack of treatment effect. Kaplan-Meier
survival analysis indicated no treatment effect on the overall lifespan of
transgenic G37R(29) animals in either cohort. Commercial male control
vs. treatment p = 0.9666; Commercial female control vs. treatment
p = 0.9120; Collaborator male control vs. treatment p = 0.5616; Collaborator
female control vs. treatment p = 0.8613.
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